Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses

Immunology and Cell Biology

Volumn 89, Issue 1, 2011, Pages 81-89

  Sirskyj, Danylo ^a   Diaz Mitoma, Francisco ^a   Golshani, Ashkan ^b   Kumar, Ashok ^c,d   Azizi, Ali ^a,c,d  

^a Variation Biotechnologies Inc   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

epitope mapping; HIV; hypervariable viruses; peptide vaccines; vaccinomics

Indexed keywords

ANTIGEN; AVIAN INFLUENZA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; PEPTIDE VACCINE; SWINE INFLUENZA VACCINE; VIRUS VACCINE;

ALGORITHM; ANTIGEN ANTIBODY REACTION; AVIAN INFLUENZA; B LYMPHOCYTE; BIOINFORMATICS; DRUG DESIGN; DRUG SYNTHESIS; EPITOPE MAPPING; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; SWINE INFLUENZA; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, VIRAL; COMPUTATIONAL BIOLOGY; EPITOPE MAPPING; HUMANS; INFLUENZA VACCINES; LYMPHOCYTES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL VACCINES;

AVES; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; SUIDAE;

EID: 78651096072     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.65     Document Type: Review

References (107)

1. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009; 10: 837-852.
2. Flower DR. Bioinformatics for Vaccinology. John Wiley and Sons, West Sussex, UK, 2008.
3. De Groot AS, Berzofsky JA. From genome to vaccine-new immunoinformatics tools for vaccine design. Methods 2004; 34: 425-428.
4. De Groot AS. Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 2006; 11: 203-209.
5. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219.
6. Donnes P, Elofsson A. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 2002; 3: 25.
7. Liu W, Meng X, Xu Q, Flower DR, Li T. Quantitative prediction of mouse class I MHC peptide binding affinity using support vector machine regression (SVR) models. BMC Bioinformatics 2006; 7: 182.
8. Wan J, Liu W, Xu Q, Ren Y, Flower DR, Li T. SVRMHC prediction server for MHCbinding peptides. BMC Bioinformatics 2006; 7: 463.
9. Noguchi H, Kato R, Hanai T, Matsubara Y, Honda H, Brusic V et al. Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. J Biosci Bioeng 2002; 94: 264-270.
10. Burden FR, Winkler DA. Predictive Bayesian neural network models of MHC class II peptide binding. J Mol Graph Model 2005; 23: 481-489.
11. Reche PA, Reinherz EL. PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res 2005; 33: W138-W142.
12. Davies MN, Hattotuwagama CK, Moss DS, Drew MG, Flower DR. Statistical deconvolution of enthalpic energetic contributions to MHC-peptide binding affinity. BMC Struct Biol 2006; 6: 5.
13. Doytchinova IA, Walshe V, Borrow P, Flower DR. Towards the chemometric dissection of peptide-HLA-A*0201 binding affinity: comparison of local and global QSAR models. J Comput Aided Mol Des 2005; 19: 203-212.
14. Azizi A, Anderson DE, Ghorbani M, Gee K, Diaz-Mitoma F. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. BMC Immunol 2006; 7: 25.
15. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354-2360.
16. Naas T, Ghorbani M, varez-Maya I, Lapner M, Kothary R, De Repentigny Y et al. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 2005; 86: 2185-2196.
17. Onafuwa-Nuga A, Telesnitsky A. The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev 2009; 73: 451-480, Table.
18. Gao F, Robertson DL, Carruthers CD, Li Y, Bailes E, Kostrikis LG et al. An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). J Virol 1998; 72: 10234-10241.
19. Fiers W, De FM, Birkett A, Neirynck S, Min JW. A universal human influenza A vaccine. Virus Res 2004; 103: 173-176.
20. Masignani V, Rappuoli R, Pizza M. Reverse vaccinology: a genome-based approach for vaccine development. Expert Opin Biol Ther 2002; 2: 895-905. (Pubitemid 36033255)
21. Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science 2003; 302: 602.
22. Chen GL, Subbarao K. Live attenuated vaccines for pandemic influenza. Curr Top Microbiol Immunol 2009; 333: 109-132.
23. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002; 15: 295-323.
24. Lim KI, Lang T, Lam V, Yin J. Model-based design of growth-attenuated viruses. PLoS Comput Biol 2006; 2: e116.
25. Arnon R, Ben-Yedidia T. Old and new vaccine approaches. Int Immunopharmacol 2003; 3: 1195-1204.
26. Azizi A, Diaz-Mitoma F. Viral peptide immunogens: current challenges and opportunities. J Pept Sci 2007; 13: 776-786.
27. Kawada M, Igarashi H, Takeda A, Tsukamoto T, Yamamoto H, Dohki S et al. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine- based control of simian immunodeficiency virus replication in rhesus macaques. J Virol 2006; 80: 1949-1958.
28. Purcell AW, Zeng W, Mifsud NA, Ely LK, Macdonald WA, Jackson DC. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J Pept Sci 2003; 9: 255-281.
29. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6: 404-414.
30. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M et al. Prototype Alzheimers disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174: 1580-1586.
31. Udhayakumar V, Anyona D, Kariuki S, Shi YP, Bloland PB, Branch OH et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42- kDa domain of the plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 1995; 154: 6022-6030.
32. Jung MC, Diepolder HM, Pape GR. T cell recognition of hepatitis B and C viral antigens. Eur J Clin Invest 1994; 24: 641-650.
33. Lu NQ. A speculative view of immune recognition. Immunol Invest 1994; 23: 53-71.
34. Takahashi H. Antigen presentation in vaccine development. Comp Immunol Microbiol Infect Dis 2003; 26: 309-328.
35. Call MJ, Xing X, Cuny GD, Seth NP, Altmann DM, Fugger L et al. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol 2009; 182: 6342-6352.
36. Carruth LM, Greten TF, Murray CE, Castro MG, Crone SN, Pavlat W et al. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses 1999; 15: 1021-1034.
37. Nabel GJ. HIV vaccine strategies. Vaccine 2002; 20: 1945-1947.
38. Niedrig M, Gregersen JP, Fultz PN, Broker M, Mehdi S, Hilfenhaus J. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 1993; 11: 67-74.
39. + cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993; 151: 5096-5105.
40. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79: 10108-10125.
41. Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO et al. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses 1999; 15: 1685-1689.
42. Sarmati L, dEttorre G, Nicastri E, Ercoli L, Uccella I, Massetti P et al. Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment. Clin Diagn Lab Immunol 2001; 8: 822-824.
43. Srivastava IK, Ulmer JB, Barnett SW. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev Vaccines 2004; 3: S33-S52.
44. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006; 43: 500-511.
45. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccinespecific immune responses in rhesus macaques. J Virol 2007; 81: 5257-5269.
46. Azizi A, Ghorbani M, Kryworuchko M, Aucoin S, Diaz-Mitoma F. Potency of cellmediated immune responses to different combined HIV-1 immunogens in a humanized murine model. Hum Vaccin 2005; 1: 170-176.
47. + T cell-immune responses in HLA-A2.1 mice. Curr HIV Res 2007; 5: 211-219.
48. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006; 346: 151-168.
49. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312: 1530-1533.
50. Rowland-Jones SL, Dong T, Fowke KR, Fowke KR, Kimani J, Krausa P et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102: 1758-1765.
51. EpiVax Inc Technical Platform (http://www epivax.com/platform/). 2009.
52. Algonomics 2009.
53. Johnson KL, Ovsyannikova IG, Mason CJ, Bergen III HR, Poland GA. Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine 2009; 28: 38-47.
54. Davies MN, Flower DR. Harnessing bioinformatics to discover new vaccines. Drug Discov Today 2007; 12: 389-395.
55. Schreiber A, Humbert M, Benz A, Dietrich U. 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. J Comput Chem 2005; 26: 879-887.
56. Kulkarni-Kale U, Bhosle S, Kolaskar AS. CEP: a conformational epitope prediction server. Nucleic Acids Res 2005; 33: W168-W171.
57. Haste AP, Nielsen M, Lund O. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci 2006; 15: 2558-2567.
58. Pizzi E, Cortese R, Tramontano A. Mapping epitopes on protein surfaces. Biopolymers 1995; 36: 675-680.
59. Kolaskar AS, Kulkarni-Kale U. Prediction of three-dimensional structure and mapping of conformational epitopes of envelope glycoprotein of Japanese encephalitis virus. Virology 1999; 261: 31-42.
60. Kulkarni-Kale U. Prediction of 3D Structure and Function of Proteins and Peptides. University of Pune: India, 2003.
61. Batori V, Friis EP, Nielsen H, Roggen EL. An in silico method using an epitope motif database for predicting the location of antigenic determinants on proteins in a structural context. J Mol Recognit 2006; 19: 21-29.
62. Blythe MJ, Flower DR. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci 2005; 14: 246-248.
63. Ponomarenko JV, Bourne PE. Antibody-protein interactions: benchmark datasets and prediction tools evaluation. BMC Struct Biol 2007; 7: 64.
64. Greenbaum JA, Andersen PH, Blythe M, Bui HH, Cachau RE, Crowe J et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit 2007; 20: 75-82.
65. Sweredoski MJ, Baldi P. PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. Bioinformatics 2008; 24: 1459-1460.
66. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990; 276: 172-174.
67. Dominguez M, Echaide I, Echaide ST, Mosqueda J, Cetrá B, Suarez CE et al. In silico predicted conserved B-cell epitopes in the merozoite surface antigen-2 family of B. bovis are neutralization sensitive. Vet Parasitol 2010; 167: 216-226.
68. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci USA 2007; 104: 246-251.
69. Sirskyj D, Weltzin R, Golshani A, Anderson D, Bozic J, Diaz-Mitoma F et al. Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin-streptavidin conjugated antibodies. J Virol Methods 2010; 163: 459-464.
70. Dandekar T, Snel B, Huynen M, Bork P. Conservation of gene order: a fingerprint of proteins that physically interact. Trends Biochem Sci 1998; 23: 324-328.
71. Pellegrini M, Marcotte EM, Thompson MJ, Eisenberg D, Yeates TO. Assigning protein functions by comparative genome analysis: protein phylogenetic profiles. Proc Natl Acad Sci USA 1999; 96: 4285-4288.
72. Lu L, Lu H, Skolnick J. MULTIPROSPECTOR: an algorithm for the prediction of protein-protein interactions by multimeric threading. Proteins 2002; 49: 350-364.
73. Han DS, Kim HS, Jang WH, Lee SD, Suh JK. PreSPI: a domain combination based prediction system for protein-protein interaction. Nucleic Acids Res 2004; 32: 6312-6320.
74. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D. The database of interacting proteins: 2004 update. Nucleic Acids Res 2004; 32: D449-D451
75. Shen J, Zhang J, Luo X, Zhu W, Yu K, Chen K et al. Predicting protein-protein interactions based only on sequences information. Proc Natl Acad Sci USA 2007; 104: 4337-4341.
76. Pitre S, Dehne F, Chan A, Cheetham J, Duong A, Emili A et al. PIPE: a protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairs. BMC Bioinformatics 2006; 7: 365.
77. Pitre S, North C, Alamgir M, Jessulat M, Chan A, Luo X et al. Global investigation of protein-protein interaction in yeast saccharomyces cerevisiae using re-occurring short polypeptide sequences. Nucleic Acids Res 2008; 36: 4286-4294.
78. Neduva V, Linding R, Su-Angrand I, Stark A, de Masi F, Gibson TJ et al. Systematic discovery of new recognition peptides mediating protein interaction networks. PLoS Biol 2005; 3: e405.
79. Yuki Y, Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 2009; 8: 1083-1097.
80. Brayden DJ, Jepson MA, Baird AW. Keynote review: intestinal Peyers patch M cells and oral vaccine targeting. Drug Discov Today 2005; 10: 1145-1157.
81. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45-S53.
82. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005; 23: 5599-5617.
83. Giannasca PJ, Giannasca KT, Leichtner AM, Neutra MR. Human intestinal M cells display the sialyl Lewis A antigen. Infect Immun 1999; 67: 946-953.
84. Terahara K, Yoshida M, Igarashi O, Nochi T, Pontes GS, Hase K et al. Comprehensive gene expression profiling of Peyers patch M cells, villous M-like cells, and intestinal epithelial cells. J Immunol 2008; 180: 7840-7846.
85. Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009; 462: 226-230.
86. Sette A, Livingston B, McKinney D, Appella E, Fikes J, Sidney J et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 2001; 29: 271-276.
87. Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles C et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci USA 1989; 86: 3296-3300.
88. Alexander J, del Guercio MF, Frame B, Maewal A, Sette A, Nahm MH et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Vaccine 2004; 22: 2362-2367.
89. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 2002; 168: 5499-5506.
90. McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, Chesnut RW et al. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol 2004; 173: 1941-1950.
91. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J et al. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods 2004; 34: 476-487.
92. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12: 585-592.
93. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996; 156: 2616-2623.
94. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181: 1365-1372.
95. Vider-Shalit T, Raffaeli S, Louzoun Y. Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. Mol Immunol 2007; 44: 1253-1261.
96. Peters HO, Mendoza MG, Capina RE, Luo M, Mao X, Gubbins M et al. An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani Sex Worker Cohort. J Virol 2008; 82: 1980-1992.
97. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhutter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 2003; 171: 1741-1749.
98. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 2006; 20: 1923-1930.
99. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006; 352: 438-449.
100. Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A et al. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 2000; 74: 7096-7107.
101. Frahm N, Kaufmann DE, Yusim K, Muldoon M, Kesmir C, Linde CH et al. Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol 2007; 179: 6638-6650.
102. Meyer D, Anderson DE, Gardner MB, Torres JV. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques. AIDS Res Hum Retroviruses 1998; 14: 751-760.
103. Azizi A, Anderson DE, Torres JV, Ogrel A, Ghorbani M, Soare C et al. Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol 2008; 180: 2174-2186.
104. Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GMCSF in a phase I trial. Vaccine 2009; 27: 243-249.
105. Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K et al. A phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001; 19: 3033-3042.
106. Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci 2009; 100: 1935-1942.
107. Fiers W, De FM, El BK, Schepens B, Roose K, Schotsaert M et al. M2e-based universal influenza A vaccine. Vaccine 2009; 27: 6280-6283.